A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Hypertension

In brief

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Key facts

Study ID

NCT00389519

Run by

Pfizer

People needed

422

Starts

2006-10-01

Expected to finish

2007-11-01

Last updated by the study team

2012-06-11

Who can join

Age: 6 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
• The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
• The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
• Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
• Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

You may not qualify if…

• Bilateral renal artery stenosis.
• Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
• Severe hypertension.
• Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
• Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
• A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
• Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
• History of pancreatitis (active or inactive).
• Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.

Where it is running

• Woodland International Research Group, LLC — Little Rock, Arkansas, United States
• Impact Clinical Research — Beverly Hills, California, United States
• Neufeld Medical Group — Los Angeles, California, United States
• Almon Clinical Research, Inc. — Orange, California, United States
• Pediatrics in Brevard — Cocoa Beach, Florida, United States
• Watson Clinic Center for Research, Inc. — Lakeland, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Medical College of Georgia — Augusta, Georgia, United States
• Hawaii Pacific Health — Honolulu, Hawaii, United States
• Nephrology and Hypertension Consultants — Park Ridge, Illinois, United States
• Tinley Park Pediatric Associates — Tinley Park, Illinois, United States
• Kosair Children's Hospital — Louisville, Kentucky, United States
• Louisiana State University — Shreveport, Louisiana, United States
• Craig Spiegel, MD — Bridgeton, Missouri, United States
• Impact Clinical Trials — Las Vegas, Nevada, United States
• Children's Heart Center — Las Vegas, Nevada, United States
• Premier Clinical Research Group — Toms River, New Jersey, United States
• SUNY Upstate Syracuse, Department of Pediatrics — Syracuse, New York, United States
• Hartrich Aquino & Hrab, PC — Williamsville, New York, United States
• Western Wake Pediatrics — Cary, North Carolina, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• Duke Pediatric Clinical Research Program — Durham, North Carolina, United States
• North Carolina Children's and Adults Clinical Research Foundation — Sylva, North Carolina, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• UAMS College of Medicine/ Arkansas Children's Hospital — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.